Avalo Therapeutics Inc.

NASDAQ: AVTX · Real-Time Price · USD
9.05
0.10 (1.12%)
At close: Aug 15, 2025, 3:59 PM
9.24
2.10%
After-hours: Aug 15, 2025, 07:50 PM EDT

Avalo Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
441K 1.92M 18.05M 5.4M
Cost of Revenue
-366K 1.28M 3.43M 1.49M
Gross Profit
807K 640K 14.62M 3.91M
Operating Income
-68.51M -27.35M -37.44M -82.13M
Interest Income
n/a n/a n/a n/a
Pretax Income
-35.02M -31.53M -41.63M -84.55M
Net Income
-35.13M -31.54M -41.66M -84.35M
Selling & General & Admin
17.24M 10.3M 20.71M 24.66M
Research & Development
52.08M 13.78M 31.31M 59.84M
Other Expenses
n/a 3.91M 38K 1.55M
Operating Expenses
69.32M 27.99M 52.06M 86.04M
Interest Expense
n/a 3.42M 4.17M 2.39M
Selling & Marketing Expenses
789K 33K 76K 2.83M
Cost & Expenses
68.95M 29.27M 55.49M 87.53M
Income Tax Expense
114K 14K 28K -196K
Shares Outstanding (Basic)
8.13M 277.73K 39.2K 36.19K
Shares Outstanding (Diluted)
10.78M 277.73K 39.2K 36.19K
EPS (Basic)
-4.32 -113.58 -1.06K -2.33K
EPS (Diluted)
-3.26 -113.58 -1.06K -2.33K
EBITDA
-68.34M -23.29M -37.29M -80.5M
EBIT
-68.51M -23.44M -37.46M -82.15M
Depreciation & Amortization
169K 158K 166K 1.66M